<DOC>
	<DOCNO>NCT00132431</DOCNO>
	<brief_summary>The purpose research study effect safety Sensipar approve Food Drug Administration ( FDA ) patient kidney failure treat dialysis uncontrolled secondary hyperparathyroidism ( HPT ) .</brief_summary>
	<brief_title>START : Sensipar Treatment Algorithm Reach K/DOQI Targets Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism</brief_title>
	<detailed_description>The purpose study : - To assess effectiveness treatment algorithm include Sensipar bio-intact parathyroid hormone ( biPTH ) , adjust serum calcium ( Ca ) , serum phosphorus ( P ) , calcium-phosphorus product ( Ca x P ) level management SHPT CKD subject dialysis determine achievement National Kidney Foundation Kidney Disease Outcomes Quality Initiative ( K/DOQI ) Guideline target . - To assess use vitamin D sterols phosphate binder Sensipar incorporate treatment SHPT . - To assess safety tolerability Sensipar .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Subjects chronic kidney disease receive dialysis least one month first dose study medication clinically stable . Adults least 18 year age give write informed consent . Out target PTH value , define recent historical measurement biPTH &gt; 160 pg/mL within 3 month prior inform consent signature . Serum calcium &gt; /= 8.4 mg/dL within one month prior inform consent signature . Unstable medical condition , define hospitalize within 30 day Day 1 , otherwise unstable judgement investigator . Hospitalization solely dialysis vascular access revision qualify unstable medical condition . Parathyroidectomy 3 month Day 1 . Current gastrointestinal disorder may associate impaired absorption orally administer medication inability swallow tablet . Use investigational drug device participation trial investigational drug device ( except experimental dialysis machine ) within 30 day enrollment study . Any investigational procedure . Females childbearing potential pregnant ( e.g. , positive serum pregnancy test ) breast feeding . Females child bear potential refuse use highly effective contraceptive measure ( determine investigator ) throughout study . Hypersensitivity Sensipar component . Previously participate Sensipar study , received/is receive Sensipar commercially available product . Disorder would compromise ability subject give write informed consent and/or comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>calcimimetic</keyword>
	<keyword>cinacalcet</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>secondary hyperparathyroidism</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>